Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

624
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
624
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

588
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
588
Paracrine Signaling01:21

Paracrine Signaling

60.2K
Paracrine signaling allows cells to communicate with their immediate neighbors via secretion of signaling molecules. Such a signal can only trigger a response in nearby target cells because the signal molecules degrade quickly or are inactivated if not taken up. Prominent examples of paracrine signaling include nitric oxide signaling in blood vessels, synaptic signaling of neurons, the blood clotting system, tissue repair/wound healing, and local allergic skin reactions. Nitric oxide as a...
60.2K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

3.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CMR Reveals the Influence of Trigger and Classification on the Myocardial Tissue Response in Takotsubo Syndrome.

Circulation. Cardiovascular imaging·2026
Same author

Correction: Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified Hepatitis B Virus transcripts.

PLoS pathogens·2026
Same author

Clinically Significant Infections in Surgical Mortality.

ANZ journal of surgery·2026
Same author

Changes in Surgical Admissions and Outcomes During and After the COVID-19 Pandemic: An Exploration of the Australian and New Zealand Audit of Surgical Mortality (ANZASM).

ANZ journal of surgery·2026
Same author

Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Enhancing knowledge of hypertension among general practitioners in Pakistan through a Train-The-Trainer initiative.

PloS one·2025

Related Experiment Video

Updated: Mar 18, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.4K

New Developments in Platelet Cyclic Nucleotide Signalling: Therapeutic Implications.

Nathan E K Procter1, Nicola L Hurst1, Vivek B Nooney2

  • 1Basil Hetzel Institute for Translational Research, The Queen Elizabeth Hospital, The University of Adelaide, Cardiology Unit, 28 Woodville Rd, Woodville South, Adelaide, SA, 5011, Australia.

Cardiovascular Drugs and Therapy
|July 1, 2016
PubMed
Summary
This summary is machine-generated.

Impaired platelet response to nitric oxide (NO) and prostacyclin (PGI2) can increase thrombosis risk and reduce drug effectiveness. Restoring NO and PGI2 signaling may improve treatment outcomes for cardiovascular diseases.

Keywords:
Adenylate cyclaseClopidogrelNitric oxidePlateletProstacyclinSoluble guanylate cyclase

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K

Related Experiment Videos

Last Updated: Mar 18, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.4K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K

Area of Science:

  • Cardiovascular Physiology
  • Platelet Biology
  • Pharmacology

Background:

  • Altered platelet physiology is linked to thrombosis in cardiovascular disease.
  • Excessive platelet activation can stem from pro-aggregatory pathways or impaired anti-aggregatory autacoids like nitric oxide (NO) and prostacyclin (PGI2).
  • Diminished platelet response to NO ('NO resistance') is observed in conditions like myocardial ischemia and heart failure, linked to reactive oxygen species and soluble guanylate cyclase dysfunction.

Purpose of the Study:

  • To review recent developments in understanding impaired platelet response to NO and PGI2.
  • To explore the implications of impaired PGI2/adenylate cyclase (AC) signaling on thrombotic risk and drug efficacy.
  • To discuss emerging therapeutic strategies for thrombotic disorders related to these signaling pathways.

Main Methods:

  • Review of existing literature on platelet function, NO and PGI2 signaling pathways.
  • Analysis of studies investigating platelet response in cardiovascular conditions.
  • Examination of the relationship between AC signaling and the efficacy of anti-platelet drugs like clopidogrel.

Main Results:

  • Impaired platelet response to NO is documented in various cardiovascular diseases, potentially reversible with pharmacotherapy.
  • Platelet response to prostaglandin E1 (PGE1) is frequently impaired in symptomatic myocardial ischemia.
  • Impaired PGI2/AC signaling may increase thrombotic risk and reduce the efficacy of anti-platelet agents targeting the P2Y12 receptor.

Conclusions:

  • Platelet resistance to NO and impaired PGI2/AC signaling are significant factors in thrombotic disorders.
  • The integrity of platelet AC signaling influences patient response to anti-platelet drugs like clopidogrel.
  • Targeting NO and PGI2 signaling pathways offers potential therapeutic implications for managing thrombosis in cardiovascular disease.